{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:48:34Z","timestamp":1753876114670,"version":"3.41.2"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Heart involvement represents the most ominous prognostic factor in light-chain amyloidosis (AL), often foreclosing curative therapies such as high-dose chemotherapy followed by autologous stem cell transplantation (ASCT). Heart transplantation (HTx) may be considered before ASCT in rigorously selected cases of advanced AL cardiac amyloidosis (CA). In ASCT-ineligible patients, chemotherapy with cyclophosphamide, bortezomib, and dexamethasone combined (CyBorD) regimen, even at low-dose, is feasible and effective in obtaining hematological and organ response.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case Summary<\/jats:title>\n                  <jats:p>A previously healthy 50-year-old woman presented with severely symptomatic new-onset heart with preserved ejection fraction, significant cardiac hypertrophy, and an \u2018apical sparing\u2019 pattern. Bone marrow and abdominal fat biopsy revealed AL amyloidosis due to a smouldering micromolecular \u03bb-type myeloma with severe cardiac involvement, and the patient was judged a good candidate to HTx followed by ASCT. Despite fragile conditions, she tolerated a full course of low-dose combination therapy with bortezomib and was withdrawn from HTx list because of unexpected persistent complete hematologic response and major cardiac improvement. Disease remission was achieved in the long term (&amp;gt;3 years).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>We report a case of exceptional persistent hematologic and cardiac response after CyBorD therapy in a patient with advanced AL-CA who left the transplantation lists (both HTx and ASCT). In ASCT-ineligible patients, chemotherapy with CyBorD regimen, even at low-dose, can lead to durable remission of the disease with excellent cardiac response.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcr\/ytac130","type":"journal-article","created":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T22:29:10Z","timestamp":1648160950000},"source":"Crossref","is-referenced-by-count":1,"title":["Light-chain cardiac amyloidosis: a case report of extraordinary sustained pathological response to cyclophosphamide, bortezomib, and dexamethasone combined therapy"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3307-0825","authenticated-orcid":false,"given":"Aldostefano","family":"Porcari","sequence":"first","affiliation":[{"name":"Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste , Via P. Valdoni 7, 34100, Trieste, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Pagura","sequence":"additional","affiliation":[{"name":"Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste , Via P. Valdoni 7, 34100, Trieste, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maddalena","family":"Rossi","sequence":"additional","affiliation":[{"name":"Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste , Via P. Valdoni 7, 34100, Trieste, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marika","family":"Porrazzo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI) , Trieste, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franca","family":"Dore","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste , Trieste, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8241-9726","authenticated-orcid":false,"given":"Rossana","family":"Bussani","sequence":"additional","affiliation":[{"name":"Center for Diagnosis and Treatment of Cardiomyopathies, Cardiothoracic Department, Institute of Pathological Anatomy and Histology, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste , Trieste, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1022-3131","authenticated-orcid":false,"given":"Marco","family":"Merlo","sequence":"additional","affiliation":[{"name":"Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste , Via P. Valdoni 7, 34100, Trieste, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2700-8478","authenticated-orcid":false,"given":"Gianfranco","family":"Sinagra","sequence":"additional","affiliation":[{"name":"Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste , Via P. Valdoni 7, 34100, Trieste, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,3,22]]},"reference":[{"key":"2024051617582950000_ytac130-B1","doi-asserted-by":"crossref","first-page":"E142","DOI":"10.1093\/eurheartj\/suaa080","article-title":"Cardiac amyloidosis: do not forget to look for it","volume":"22","author":"Porcari","year":"2020","journal-title":"Eur Hear J Suppl"},{"key":"2024051617582950000_ytac130-B2","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2024051617582950000_ytac130-B3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejim.2020.09.025","article-title":"Transthyretin amyloid cardiomyopathy: an uncharted territory awaiting discovery","volume":"82","author":"Porcari","year":"2020","journal-title":"Eur J Intern Med"},{"key":"2024051617582950000_ytac130-B4","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1002\/ehf2.13411","article-title":"Current patterns of beta-blocker prescription in cardiac amyloidosis: an Italian nationwide survey","volume":"8","author":"Tini","year":"2021","journal-title":"ESC Hear Fail"},{"key":"2024051617582950000_ytac130-B5","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1182\/bloodadvances.2020002219","article-title":"Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis","volume":"4","author":"Basset","year":"2020","journal-title":"Blood Adv"},{"key":"2024051617582950000_ytac130-B6","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"key":"2024051617582950000_ytac130-B7","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1182\/blood-2005-08-3253","article-title":"Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis","volume":"107","author":"Gillmore","year":"2006","journal-title":"Blood"},{"key":"2024051617582950000_ytac130-B8","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jchf.2019.12.013","article-title":"Outcomes in patients with cardiac amyloidosis undergoing heart transplantation","volume":"8","author":"Barrett","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2024051617582950000_ytac130-B9","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"2024051617582950000_ytac130-B10","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"key":"2024051617582950000_ytac130-B11","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","article-title":"Screening for transthyretin amyloid cardiomyopathy in everyday practice","volume":"7","author":"Witteles","year":"2019","journal-title":"JACC Hear Fail"},{"key":"2024051617582950000_ytac130-B12","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ehf2.13606","article-title":"Prognostic significance of unexplained left ventricular hypertrophy in patients undergoing carpal tunnel surgery","volume":"9","author":"Porcari","year":"2021","journal-title":"ESC Hear Fail"},{"key":"2024051617582950000_ytac130-B13","article-title":"A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization\u2014the first insight from the AC-TIVE Study","author":"Merlo","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2024051617582950000_ytac130-B14","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jchf.2020.03.007","article-title":"Utility of Biomarkers in Cardiac Amyloidosis","volume":"8","author":"Pregenzer-Wenzler","year":"2020","journal-title":"JACC Hear Fail"},{"key":"2024051617582950000_ytac130-B15","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood.2020006913","article-title":"Management of AL amyloidosis in 2020","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"key":"2024051617582950000_ytac130-B16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2459\/JCM.0000000000001094","article-title":"Emerging therapy in light-chain and acquired transthyretin-related amyloidosis: an Italian single-centre experience in heart transplantation","volume":"22","author":"Di Nora","year":"2021","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2024051617582950000_ytac130-B17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/MOT.0000000000000756","article-title":"Heart transplantation in cardiac storage diseases: data on Fabry disease and cardiac amyloidosis","volume":"25","author":"Di Nora","year":"2020","journal-title":"Curr Opin Organ Transplant"},{"key":"2024051617582950000_ytac130-B18","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"2024051617582950000_ytac130-B19","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcr\/advance-article-pdf\/doi\/10.1093\/ehjcr\/ytac130\/42974454\/ytac130.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/6\/4\/ytac130\/57708027\/ytac130.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/6\/4\/ytac130\/57708027\/ytac130.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T18:02:32Z","timestamp":1715882552000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/doi\/10.1093\/ehjcr\/ytac130\/6552215"}},"subtitle":[],"editor":[{"given":"Pierpaolo","family":"Pellicori","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Lilit","family":"Baghdasaryan","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Christoph Clemens","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Sara","family":"Monosilio","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Gon\u00e7alo","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,3,22]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4,13]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/ytac130","relation":{},"ISSN":["2514-2119"],"issn-type":[{"type":"electronic","value":"2514-2119"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2022,3,22]]},"article-number":"ytac130"}}